Mary Wilson
Well-known member
Last updated March 14, 2022
Authors
Adarsh Bhimraj,1 Rebecca L. Morgan,2 Amy Hirsch Shumaker,3 Valery Lavergne,4 Lindsey Baden,5 Vincent Chi-Chung Cheng,6 Kathryn M. Edwards,7 Rajesh Gandhi,8 Jason Gallagher,9William J. Muller,10 John C. O’Horo,11 Shmuel Shoham,12 M. Hassan Murad,13 Reem A. Mustafa,14 Shahnaz Sultan,15 Yngve Falck-Ytter3
Abstract
Background: There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature.
Objective: There are many pharmacologic therapies that are being used or considered for treatment of COVID-19. There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature.
Methods: In March 2020, the Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. The process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer- reviewed and grey literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations.
Results: On April 11, 2020, IDSA released online initial treatment recommendations and narrative summaries of other treatments under evaluation. Since that time, the guideline panel and methodologists have continued to monitor the literature and issue updates and addendums to these guidelines in response to evolving research.
Conclusions: Since the inception of its work, the panel has expressed the overarching goal that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments.
https://www.idsociety.org/globalass...tment/idsa-covid-19-gl-tx-and-mgmt-v7.0.1.pdf
Authors
Adarsh Bhimraj,1 Rebecca L. Morgan,2 Amy Hirsch Shumaker,3 Valery Lavergne,4 Lindsey Baden,5 Vincent Chi-Chung Cheng,6 Kathryn M. Edwards,7 Rajesh Gandhi,8 Jason Gallagher,9William J. Muller,10 John C. O’Horo,11 Shmuel Shoham,12 M. Hassan Murad,13 Reem A. Mustafa,14 Shahnaz Sultan,15 Yngve Falck-Ytter3
Abstract
Background: There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature.
Objective: There are many pharmacologic therapies that are being used or considered for treatment of COVID-19. There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature.
Methods: In March 2020, the Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. The process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer- reviewed and grey literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations.
Results: On April 11, 2020, IDSA released online initial treatment recommendations and narrative summaries of other treatments under evaluation. Since that time, the guideline panel and methodologists have continued to monitor the literature and issue updates and addendums to these guidelines in response to evolving research.
Conclusions: Since the inception of its work, the panel has expressed the overarching goal that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments.
https://www.idsociety.org/globalass...tment/idsa-covid-19-gl-tx-and-mgmt-v7.0.1.pdf